Friday, 16 October 2026European Markets

MOURY CONSTRUCT Stock Rises By 29% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of MOURY CONSTRUCT (BEL 20: MOUR.BR) rose by a staggering 29.45% in 21 sessions from €292 to €378.00 at 02:21 EST on Monday, following the last session's downward trend. BEL 20 is jumping 0.66% to €3,838.12, after two sequential sessions in a row of gains.

MOURY CONSTRUCT's last close was €378.00, 1.56% under its 52-week high of €384.00.

About MOURY CONSTRUCT

Moury Construct SA engages in the construction and renovation of residential and non-residential buildings for private and public markets in Belgium. The company undertakes public and private buildings, commercial areas, halls of structures, renovation and restoration, and industries and services projects. It is also involved in the general joinery, and thermal and acoustic insulations; prefabrication of concrete elements; and promotion and real estate arrangements. The company was founded in 1920 and is based in Liège, Belgium.

Earnings Per Share

As for profitability, MOURY CONSTRUCT has a trailing twelve months EPS of €37.02.

PE Ratio

MOURY CONSTRUCT has a trailing twelve months price to earnings ratio of 10.21. Meaning, the purchaser of the share is investing €10.21 for every euro of annual earnings.

Moving Average

MOURY CONSTRUCT's value is way above its 50-day moving average of €301.36 and way higher than its 200-day moving average of €286.70.

Volume

Today's last reported volume for MOURY CONSTRUCT is 76 which is 167.85% above its average volume of 84.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jun 15, 2022, the estimated forward annual dividend rate is 8.4 and the estimated forward annual dividend yield is 2.43%.

More news about MOURY CONSTRUCT (MOUR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com